HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis
- PMID: 35000014
- DOI: 10.1007/s10072-021-05803-0
HSV encephalitis associated with off-label rituximab treatment of multiple sclerosis
References
-
- Vollmer BL, Wallach AI, Corboy JR, Dubovskaya K, Alvarez E, Kister I (2020) Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol 7(9):1477–1487 - DOI
-
- Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F (2021) Rituximab for the treatment of multiple sclerosis: a review. J Neurol. https://doi.org/10.1007/s00415-020-10362-z
-
- Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1(7):e184169 - DOI
-
- Epstein DJ, Dunn J, Deresinski S (2018) Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 5(8):ofy174 - DOI
-
- Thong L, Plant BJ, McCarthy J, Murphy DM (2016) Herpetic tracheitis in association with rituximab therapy. Respirol Case Rep 4(4):e00158 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources